Drug
Dt402
Dt402: highest development phase Phase 2, developed by Definium Therapeutics US, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Definium Therapeutics US, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) NCT07303907 | Phase 2 | Autism Spectrum Disorder |
Latest
No recent events.
Follow Dt402 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.